Pfizer

U.S. stocks rose as investors as the S&P 500 traded at new historical highs and clearing its 2014 losses. Investors shrugged off disappointing earning reports and economic data and chose to focus on several prominent merger and acquisition activities. The S&P 500 hit a new intra-day...

Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company to snap up shares. Here are some stocks that have seen insider buying recently. Aircastle Japanese trading company Marubeni Corp. has been scooping up batches of Aircastle (NYSE: AYR) shares since last...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

U.S. stocks rose today as investors and traders felt that there were plenty of bargains in the market to be found. "Today is just a bounce. I don't think there is really that much behind it, other than some bargain hunters stepping in," Robert Pavlik, a chief market strategist said to CNBC....

U.S. stocks continued its losses on an accelerated basis on Monday. Investors are in clear panic mode following a report that U.S manufacturing activity expanded at a slower pace in January. The Dow plunged more than 300 points while the S&P 500 and Nasdaq both fell more than two percent as...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

U.S. stocks picked up where they left off on Friday and declined today as investors have plenty on their mind. With earnings being a mixed bag, investors are looking at emerging markets and economic data to support a bullish case for equities. On the emerging market front, investors remain...

The earnings crunch is on this week. Highlights will include reports from Amazon.com, Apple, Boeing, Comcast, Facebook, Google and Yahoo! All of them are expected to report year-over-year growth in per-share earnings. But analysts are looking for declining profits from the likes of Caterpillar,...

Major indices reversed Monday's losses and posted strong gains following a better than expected retail sales report and a luke-warm start to earnings season. Related: Stocks Higher, But Dollar Indecisive After Retail Sales Release Philidalphia's Fed chief Charles Plosser said that he wants QE...

Although investors and analysts are optimistic about economic growth going into 2014, their expectations also include a healthy dose of caution according to Reuters. Positive factors include a late rally in the stock market in 2013 and a U.S. Federal Reserve decision to begin tapering its...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

Stock futures pointed to a lower open following premarket data revealing that the U.S. economy and job market are improving faster and stronger than expected. Selling began at the bell and continued for the entire day as major indices failed to hold on to any rallying gains. Investors and...

Investors appeared to be nervous going in to yesterday's close, a sentiment which continued at today's open. With little encouraging data coming out of the holiday shopping figures, investors and traders nervously await Friday's Labor Department November jobgs report which could help determine...

If you’re thinking that the BlackBerry (NASDAQ: BBRY) hemorrhage has come to an end with interim CEO John Chen at the helm, that doesn’t appear to be true. The company’s 2013 has been another to forget. The stock is down 45 percent year to date and 85 percent over the past five years but none...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...